Released Nov 4, 2026, after the close
10-Q filed Nov 4, 2026, 35 days after period end · 0001588978-26-000039
PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $98.29M | $83.33M | $58.37M | $35.10M |
| Net Income | -$26.52M | -$21.41M |
PROCEPT BioRobotics Corp · CIK 1588978 · Engraved from SEC EDGAR
| -$20.97M |
| -$24.62M |
| EPS Diluted | -$0.46 | -$0.38 | -$0.40 | -$0.51 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Total revenue was $98.3 million for the third quarter of 2026, an increase of 18% over the prior year period, and net loss was $26.5 million compared to a loss of $21.4 million.¶2¶3
Operating expenses in the third quarter of 2026 were $92.5 million, compared with $77.2 million in the prior year period.¶4
The Company reiterated full year 2026 revenue guidance of $390 million to $410 million and U.S. procedure volume guidance of 54,000-56,000.¶5¶6
The Company reiterated full year 2026 adjusted EBITDA loss guidance of $35 million to $30 million.¶7
Cash, cash equivalents and restricted cash totaled approximately $221.4 million as of September 30, 2026, and the Company delivered 62 U.S. HYDROS systems, including 20 replacement systems.¶8¶9